论文部分内容阅读
[目的]观察曲妥珠单抗联合长春瑞滨治疗蒽环类/紫杉醇类治疗失败的人表皮生长因子受体-2(Her-2)阳性晚期乳腺癌的临床疗效。[方法]16例Her-2阳性转移性乳腺癌患者接受曲妥珠单抗首次8mg/kg,以后6mg/kg,每3周1次联合长春瑞滨25mg/m2,d2、d9,每3周为1周期,最多6个周期后如疾病无进展则改为曲妥珠单抗6mg/kg,每3周1次维持治疗至1年或疾病进展。[结果]16例患者全部可评价疗效,有效率62.5%,其中一线治疗有效率72.7%;中位疾病进展时间(TTP)9.3个月,1年、2年生存率分别为87.5%、56.3%。最常见毒副反应为血液学毒性。与曲妥珠单抗有关的毒副反应主要有发热、寒战以及左室射血分数(LVEF)下降。[结论]曲妥珠单抗联合长春瑞滨治疗Her-2阳性的蒽环类/紫杉醇类治疗失败的转移性乳腺癌有较好的疗效,毒副反应大多可耐受。
[Objective] To observe the clinical efficacy of trastuzumab combined with vinorelbine in the treatment of human epidermal growth factor receptor-2 (Her-2) -positive advanced breast cancer with anthracycline / paclitaxel failure. [Method] Sixteen patients with Her-2 positive metastatic breast cancer received trastuzumab for the first time, 8mg / kg and 6mg / kg every 3 weeks for a combination of vinorelbine 25mg / m2, d2 and d9 every 3 weeks For 1 cycle, up to 6 cycles if the disease progresses to trastuzumab 6mg / kg, every 3 weeks of maintenance treatment to 1 year or disease progression. [Results] All of the 16 patients were evaluable. The effective rate was 62.5%, of which the first-line treatment was 72.7%. The median time to progression (TTP) was 9.3 months. The 1-year and 2-year survival rates were 87.5% . The most common toxicities are hematological toxicity. The toxic side effects associated with trastuzumab are mainly fever, chills, and decreased left ventricular ejection fraction (LVEF). [Conclusion] Trastuzumab combined with vinorelbine has a good curative effect in the treatment of Her-2-positive anthracycline / paclitaxel-failed metastatic breast cancer, and most of the toxic and side effects are tolerable.